Cadrenal Therapeutics (Nasdaq: CVKD) Granted FDA Fast Track Designation for Tecarfarin for Prevention of Systemic Thromboembolism of Cardiac Origin in Patients with End-Stage Renal Disease and Atrial Fibrillation
Retrieved on:
Monday, January 23, 2023
Therapy, Biomarker, Marketing, Ventricular fibrillation, Collection, Stroke, Priority review, New Drug Application, NDA, Kidney disease, ODD, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Accelerated approval (FDA), ESRD, Duke University, Plasma protein binding, FDA, Rare, White Light Rock & Roll Review, Patient, Atrial fibrillation, Fast Track, Food, Communication, Tecarfarin, Fast track (FDA), Assistant, Pharmaceutical industry, Medical device, Medicine
Fast Track is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need.
Key Points:
- Fast Track is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need.
- The purpose of Fast Track is to get important new drugs to the patient earlier.
- Fast Track addresses a broad range of serious conditions.
- The FDA had previously granted an Orphan Drug Designation (ODD) for tecarfarin.